VACBF (Nykode Therapeutics AS) Tax Provision: $3.40 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VACBF Nykode Therapeutics AS VACBF
22 GF Score
Price $0.32
GF Value $0.76
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Nykode Therapeutics AS Tax Provision?

Nykode Therapeutics AS VACBF -1.05% 22 Tax Provision is $3.40 Mil as of Mar. 2026. GuruFocus rates VACBF with a GF Score™ of 22/100 and a GF Value™ of $0.76 (Possible Value Trap). The stock has 1 warning sign investors should review.

Nykode Therapeutics AS's tax provision for the three months ended in Mar. 2026 was $-0.01 Mil. Its tax provision for the trailing twelve months (TTM) ended in Mar. 2026 was $3.40 Mil.

Nykode Therapeutics AS Tax Provision Historical Data

* Premium members only.

The historical data trend for Nykode Therapeutics AS's Tax Provision can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nykode Therapeutics AS Tax Provision Chart

Nykode Therapeutics AS Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Provision
Get a 7-Day Free Trial Premium Member Only 1.70 8.24 8.93 6.69 5.46

Nykode Therapeutics AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Provision Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.05 2.04 1.32 0.05 -0.01
VACBF
22GF Score
Nykode Therapeutics AS VACBF
Tax Provision is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nykode Therapeutics AS Tax Provision Calculation

Tax to be paid.

Tax Provision for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Provision →
What does a Tax Provision of $3.40 Mil mean?
Nykode Therapeutics AS (VACBF) has a Tax Provision of $3.40 Mil as of Mar. 2026. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Nykode Therapeutics AS and its competitors.
Is Nykode Therapeutics AS's Tax Provision too high?
Nykode Therapeutics AS's current Tax Provision is $3.40 Mil. Overall, Nykode Therapeutics AS has a GF Score™ of 22/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Nykode Therapeutics AS's Tax Provision compare to VRTX and REGN?
Nykode Therapeutics AS's Tax Provision of $3.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Provision for a Biotechnology company?
A good Tax Provision depends on the Biotechnology industry context. However, Tax Provision should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Provision mean?
A high Tax Provision can signal that a stock is expensive relative to its fundamentals. Provision for taxes is the amount of tax the company owes based on pre-tax income. View historical data on Nykode Therapeutics AS and its competitors. Nykode Therapeutics AS's current Tax Provision is $3.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nykode Therapeutics AS stock overvalued right now?
Based on GuruFocus' analysis, Nykode Therapeutics AS (VACBF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.76, compared to a current price of $0.32 — trading 57.7% below its estimated fair value. The current Tax Provision is $3.40 Mil. Nykode Therapeutics AS's overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Provision calculated?
Tax Provision is calculated from a company's financial statements. For Nykode Therapeutics AS (VACBF), the current Tax Provision is $3.40 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nykode Therapeutics AS (VACBF) Overvalued in 2026?

Based on GuruFocus' analysis, Nykode Therapeutics AS stock appears to be undervalued. The current stock price of $0.32 is trading 57.7% below its estimated GF Value™ of $0.76. GuruFocus considers Nykode Therapeutics AS to be Possible Value Trap.

Key valuation signals for VACBF:

  • Tax Provision: $3.40 Mil
  • GF Value™: $0.76 vs. price of $0.32 (57.7% below fair value)
  • GF Score™: 22/100 with 1 warning sign

No single metric tells the full story. See the VACBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Nykode Therapeutics AS Business Description

Address Gaustadalleen 21, Oslo Research Park, Oslo, NOR, 0349
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need using it's modular immunotherapy technology, specifically targeting antigens to Antigen Presenting Cells, which are essential for inducing rapid and long-lasting immune responses. It operates in United States of America.
22GF Score

Get the complete analysis for VACBF

Tax Provision is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.32
Price
$0.76
GF Value